Clarity Pharmaceuticals Ltd. (AU:CU6) has released an update.
Clarity Pharmaceuticals Ltd has secured a key supply agreement with SpectronRx to enhance the distribution of its copper-64 (Cu-64) isotope, crucial for the company’s radiopharmaceuticals that are currently undergoing clinical trials, including a significant Phase III trial. The new partnership is set to tackle the supply challenges of current radiodiagnostic isotopes with Cu-64’s longer half-life, facilitating more flexible and efficient PET imaging. This collaboration is expected to streamline Clarity’s supply chain network, ensuring reliable delivery of its innovative Targeted Copper Theranostic (TCT) products to the market.
For further insights into AU:CU6 stock, check out TipRanks’ Stock Analysis page.
